Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct-Dec;47(4):613-617.
doi: 10.4103/ijcm.ijcm_93_22. Epub 2022 Dec 14.

Incidence of Early Adverse Events Following Covishield (ChAdOx1 nCoV-19) Vaccination: A Prospective Study

Gajanan D Velhal  1 , Yash V Kamath  1 , Ansh S Agrawal  1 , Devanshi S Vora  1 , Vaibhav R Dwivedi  1
Affiliations

Incidence of Early Adverse Events Following Covishield (ChAdOx1 nCoV-19) Vaccination: A Prospective Study

Gajanan D Velhal et al. Indian J Community Med. 2022 Oct-Dec.

Abstract

Background: Minor adverse event following immunizations (AEFIs) are often underreported and self-treated. This study aimed to collect information regarding any and every probable adverse event experienced by the recipient of Covishield vaccine up to 10 days following the first and second dose of vaccine. To find the incidence of minor adverse events following Covishield vaccination; draw an association between adverse events and individuals' demographic factors and comorbidities; and report new adverse events, if any.

Materials and methods: A descriptive observational study was conducted among 409 participants randomly sampled from the Vaccination Centre at a Tertiary Care Hospital, Mumbai. Participants were followed up post their first and second doses to enquire about adverse events.

Results: Most commonly reported adverse events included injection site pain, tenderness, chills, fatigue, fever, and myalgia. Females reported more adverse events compared to men (p < 0.05). Younger individuals (18-24) experienced adverse events more as compared to individuals above 40 years of age (p < 0.005). Reported adverse events were lesser after the second dose in comparison with the first dose. Few participants reported dysgeusia.

Conclusions: Covishield vaccination has a mild AEFI profile, most commonly: injection site pain, tenderness, chills, and fatigue. It is hoped that the findings of this study will dispel anxiety around the adverse events of vaccination and reduce any persisting vaccine hesitancy. Effective communication with the population on vaccination will enable individuals to make educated and informed decisions.

Keywords: AEFI; COVID-19; COVISHIELD; India; immunization; incidence; vaccination; vaccines.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Incidence of adverse events after the first dose of covishield (in %)
Figure 2
Figure 2
Incidence of adverse events after the second dose of covishield (in %)
See this image and copyright information in PMC

References

    1. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19) Our World in Data. 2020. [Last accessed on 2022 Aug 16]. Available from: https://ourworldindata.org/covid-vaccinations .
    1. 31% Indians preferring covishield over covaxin covid-19 jabs: Goqii India survey. [Last accessed on 2022 Aug 16]. Available from: https://www.biospectrumindia.com/news/79/18127/31-indians-preferring-cov... .
    1. ‘Guidelines for COVID-19 Vaccination’. Ministry of Health and Family Welfare, Government of India; 2022. [Last accessed on 2022 Aug 16]. Available from: https://www.mohfw.gov.in/pdf/GuidelinesforCOVID19VaccinationofChildrenbe... .
    1. Serum institute of India-chadox1 ncov- 19 corona virus vaccine (Recombinant)-covishield. [Last accessed on 2022 Aug 16]. Available from: https://www.seruminstitute.com/product_covishield.php .
    1. IBM Corp. Released 2019. IBM SPSS Statistics for Windows. Version 26.0. Armonk, NY: IBM Corp;